BAFF CAR-T
Phase 2Cell therapy
BAFF CAR-T is one of 93 small molecule programs targeting Non-Hodgkin Lymphoma Refractory/ Relapsed. It is currently in Phase 2.
3
Indications
3
Total Trials
3
Active Trials
92
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
401 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Zofran
NovartisPreclinical
Norvir
AbbViePreclinical
Cabenuva
GSKPreclinical
BAFF CAR-T
LLuminary Therapeutics
Phase 2
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Lymphocytic Leukemia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BAFF CAR-T. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 2[1]
- Company
- LLuminary Therapeutics